Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2107
Peer-review started: May 12, 2021
First decision: July 4, 2021
Revised: July 13, 2021
Accepted: November 24, 2021
Article in press: November 24, 2021
Published online: December 15, 2021
Processing time: 217 Days and 17.8 Hours
The prevalence of diabetes is increasing worldwide, and increased diabetes frequency means an increase in the incidence of diabetes-related mortality and morbidity. Turkey stands as the country with the highest diabetes mellitus prevalence in Europe. Since commonly seen infections are associated with significantly increased morbidity and mortality, vaccination programs are now among the standard of care for diabetes mellitus. Vaccination for influenza and pneumococcal infections has gained broad acceptance worldwide.
Although current guidelines emphasize the importance of influenza and pneumococcal vaccination in diabetic patients and that physician acceptance has been reported to increase, the reported vaccination rates still remain low in many countries with different economic development. The rates of vaccination in patients with diabetes mellitus in Turkey have not been systematically evaluated so far.
The main objective of the current study was to perform a nationwide survey to explore the vaccination status for two major diseases, pneumococcus and influenza, among patients with diabetes mellitus. The secondary objective was to determine which patients tend to get vaccinated or not vaccinated.
In a multicenter, cross-sectional survey design, the TEMD Vaccination Study enrolled 454 patients with type 1 diabetes mellitus (T1DM) and 4721 patients with type 2 diabetes mellitus (T2DM), who were under followed up in 68 tertiary endocrinology clinics. Vaccination status was assessed by self-reports and medical records.
The study found 23.6% and 8% vaccination rates for influenza and pneumococcus, respectively, in patients with T1DM. The rates were 21.2% and 8% in patients with T2DM. Vaccination for both conditions was recorded in 6.6% of patients with T1DM and 5.8% of patients with T2DM. Older age and longer diabetes duration were the most common associates of vaccination for both types of diabetes. Among patients with T2DM, higher education level, statin use, and lower HbA1c level were also independently associated with higher vaccination status.
This study showed for the first time that patients with T1DM and T2DM had very low influenza and pneumococcal vaccination rates in Turkey. The findings warrant new and improved strategies to increase the awareness of vaccination among the partners involved in different levels of diabetes care, from patients to policymakers and healthcare professionals.
As vaccination programs are cost-saving by reducing diabetes-related mortality and morbidity, there is an unmet need to identify the barriers and obstacles against the acceptance of vaccination programs by the patients and healthcare programs in this population. Additionally, potential difficulties in implementing the vaccination programs at the system level need to be identified. Finally, increasing the number of patients with diabetes mellitus who are vaccinated should be prioritized as these patients are considered much defenseless against opportunistic infections.